Beta Drugs Ltd

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE351Y01019
  • NSEID: BETA
  • BSEID:
INR
1,271.90
-131.7 (-9.38%)
BSENSE

May 15

BSE+NSE Vol: 60288

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Cr
Consolidate Quarterly Results
Mar'26
Dec'25
Sep'25
Mar'25
Dec'24
Net Sales
93.96
87.27
103.39
93.76
88.29
Other Operating Income
0.00
0.00
0.00
0.00
0.00
Total Operating income
93.96
87.27
103.39
93.76
88.29
Raw Material Cost
36.78
32.50
46.40
44.23
43.73
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
-0.69
3.54
2.90
-0.26
-1.45
Employee Cost
18.68
16.82
16.48
15.18
13.91
Power Cost
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.01
0.00
0.00
-0.01
0.01
Selling and Distribution Expenses
0.00
0.00
0.00
0.00
0.00
Other Expenses
21.50
17.42
16.30
17.28
13.63
Total Expenditure (Excl Depreciation)
76.28
70.28
82.08
76.42
69.83
Operating Profit (PBDIT) excl Other Income
17.68
16.99
21.31
17.34
18.46
Other Income
2.89
2.31
2.99
3.96
0.97
Operating Profit (PBDIT)
20.57
19.30
24.30
21.30
19.43
Interest
3.94
4.43
3.61
3.29
1.88
Exceptional Items
0.00
0.00
0.00
-2.22
-2.35
Gross Profit (PBDT)
16.63
14.87
20.69
15.79
15.20
Depreciation
4.80
4.39
4.24
3.57
3.24
Profit Before Tax
11.83
10.47
16.44
12.23
11.96
Tax
2.78
1.95
4.23
3.20
3.01
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
Profit After Tax
9.05
8.52
12.22
9.03
8.95
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
Net Profit
9.05
8.52
12.22
9.03
8.95
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
9.05
8.52
12.22
9.03
8.95
Equity Capital
10.14
10.14
10.09
10.09
9.61
Face Value
10.0
10.0
10.0
10.0
10.0
Reserves
0.00
0.00
0.00
0.00
0.00
Earnings per share (EPS)
8.93
8.4
12.11
8.95
8.87
Diluted Earnings per share
8.93
8.4
12.1
9.4
8.87
Operating Profit Margin (Excl OI)
18.82%
19.47%
20.61%
18.49%
20.91%
Gross Profit Margin
17.7%
17.04%
20.01%
16.84%
17.22%
PAT Margin
9.63%
9.76%
11.82%
9.63%
10.14%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
stock-summary

Net Sales

YoY Growth in quarter ended Mar 2026 is 1.14%

stock-summary

Standalone Net Profit

YoY Growth in quarter ended Mar 2026 is 283.45%

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Mar 2026 is 85.55%

stock-summary

Interest

YoY Growth in quarter ended Mar 2026 is 2.14%

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025

Compare Quarterly Results Of Beta Drugs Ltd With
Markets Mojo
Figures in Cr
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
93.96
77.42
16.54
21.36%
Other Operating Income
0.00
0.00
0.00
Total Operating income
93.96
77.42
16.54
21.36%
Raw Material Cost
36.78
18.34
18.44
100.55%
Purchase of Finished goods
0.00
5.65
-5.65
-100.00%
(Increase) / Decrease In Stocks
-0.69
-3.26
2.57
78.83%
Employee Cost
18.68
15.52
3.16
20.36%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.01
0.00
0.01
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
21.50
23.37
-1.87
-8.00%
Total Expenditure (Excl Depreciation)
76.28
59.62
16.66
27.94%
Operating Profit (PBDIT) excl Other Income
17.68
17.80
-0.12
-0.67%
Other Income
2.89
0.67
2.22
331.34%
Operating Profit (PBDIT)
20.57
18.47
2.10
11.37%
Interest
3.94
1.82
2.12
116.48%
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
16.63
16.65
-0.02
-0.12%
Depreciation
4.80
4.43
0.37
8.35%
Profit Before Tax
11.83
13.52
-1.69
-12.50%
Tax
2.78
4.21
-1.43
-33.97%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
9.05
7.99
1.06
13.27%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
9.05
7.99
1.06
13.27%
Share in Profit of Associates
0.00
1.32
-1.32
-100.00%
Minority Interest
0.00
0.55
-0.55
-100.00%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
9.05
8.77
0.28
3.19%
Equity Capital
10.14
8.51
1.63
19.15%
Face Value
10.00
10.00
0.00
Reserves
0.00
0.00
0.00
Earnings per share (EPS)
8.93
10.31
-1.38
-13.39%
Diluted Earnings per share
8.93
10.94
-2.01
-18.37%
Operating Profit Margin (Excl OI)
18.82%
22.99%
0.00
-4.17%
Gross Profit Margin
17.70%
21.51%
0.00
-3.81%
PAT Margin
9.63%
12.03%
0.00
-2.40%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Quarterly - Net Sales
Net Sales 54.35 Cr
in Mar 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Mar 2026 is 8.09% vs -7.71% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 1.14%

Quarterly - Standalone Net Profit
Standalone Net Profit 5.33 Cr
in Mar 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Mar 2026 is 64.00% vs 115.23% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 283.45%

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 9.76 Cr
in Mar 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Mar 2026 is 49.01% vs 38.48% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 85.55%

Quarterly - Interest
Interest 2.87 Cr
in Mar 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Mar 2026 is -9.46% vs 6.73% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 2.14%

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 17.96%
in Mar 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025